Johnson & Johnson (JNJ)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Diversified Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.88% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Pfizer (PFE) Trades Below 10x Earnings. Why Does Johnson & Johnson (JNJ) Command More Than Twice the Multiple?
- Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?
- The Crash-Proof Portfolio: 5 Elite Dividend Stocks Built to Survive a Market Meltdown
- How ICOTYDE’s Long-Term Psoriasis Data At Johnson & Johnson (JNJ) Has Changed Its Investment Story
- Jim Cramer Has Soured on Intuitive Surgical (ISRG). The Reason is Johnson & Johnson
- Two of America’s Biggest Money Voices Give Opposite Advice on Dividend Stocks
- Johnson & Johnson CEO Says AI Has to Be Embraced
- Johnson & Johnson's Innovative Medicines Momentum Offsets MedTech Headwinds, RBC Capital Markets Says
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Johnson & Johnson.
Full JNJ Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.